Literature DB >> 26682936

Interleukin-10 limits increased blood pressure and vascular RhoA/Rho-kinase signaling in angiotensin II-infused mice.

Victor V Lima1, Saiprasad M Zemse2, Chin-Wei Chiao3, Gisele F Bomfim4, Rita C Tostes5, R Clinton Webb2, Fernanda R Giachini6.   

Abstract

AIMS: Interleukin-10 (IL-10) is a multi-functional cytokine with potent anti-inflammatory properties. We hypothesized that IL-10 limits increased RhoA/Rho-kinase signaling and vascular reactivity in arteries from angiotensin II (Ang II) hypertensive mice. MAIN
METHODS: Wild type (WT) and IL-10 knockout ((-/-)) mice were infused with Ang II (90ng/min) for 14days. Additionally, WT mice were infused with Ang II and simultaneously infused with exogenous IL-10 (0.5ηg/min, 14days). Aortic rings were mounted in a myograph and concentration-response curve to phenylephrine (PE) were evaluated. KEY
FINDINGS: After Ang II infusion, blood pressure responses, but not maximal contraction to PE, was greater in IL-10(-/-) mice, compared to WT. Rho-kinase inhibition (Y-27632; 10μM) resulted in a more evident reduction of PE-induced contraction in WT hypertensive mice, when compared to IL-10(-/-) hypertensive mice. IL-10 exogenous infusion prevented the blood pressure increase in Ang II-infused WT mice. The augmented PE-contraction observed in aorta from WT mice infused with Ang II was also prevented by exogenous infusion of IL-10. Additionally, Rho-kinase inhibition (Y-27632; 10μM) abolished the differences in the contractile response to PE between these groups. SIGNIFICANCE: These results demonstrate that IL-10 counteracts both the pressoric activity of Ang II as well as vascular dysfunction associated with hypertension, partially, modulating the RhoA-Rho kinase pathway. Strategies to enhance IL-10 levels during hypertension may enhance the benefits provided by regular treatments.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine; Inflammation; Vascular dysfunction

Mesh:

Substances:

Year:  2015        PMID: 26682936     DOI: 10.1016/j.lfs.2015.12.009

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  24 in total

1.  Systemic Upregulation of IL-10 (Interleukin-10) Using a Nonimmunogenic Vector Reduces Growth and Rate of Dissecting Abdominal Aortic Aneurysm.

Authors:  Matti Adam; Nigel Geoffrey Kooreman; Ann Jagger; Markus U Wagenhäuser; Dennis Mehrkens; Yongming Wang; Yosuke Kayama; Kensuke Toyama; Uwe Raaz; Isabel N Schellinger; Lars Maegdefessel; Joshua M Spin; Jaap F Hamming; Paul H A Quax; Stephan Baldus; Joseph C Wu; Philip S Tsao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

Review 2.  Renal effects of cytokines in hypertension.

Authors:  Yi Wen; Steven D Crowley
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-03       Impact factor: 2.894

Review 3.  Salt, Hypertension, and Immunity.

Authors:  A Justin Rucker; Nathan P Rudemiller; Steven D Crowley
Journal:  Annu Rev Physiol       Date:  2017-11-16       Impact factor: 19.318

4.  IL-10 treatment decreases blood pressure in male, but not female, spontaneously hypertensive rats.

Authors:  Ellen E Gillis; Jacqueline B Musall; Babak Baban; Jennifer C Sullivan
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-20

5.  Deficiency of MicroRNA-181a Results in Transcriptome-Wide Cell-Specific Changes in the Kidney and Increases Blood Pressure.

Authors:  Francine Z Marques; Geoffrey A Head; Madeleine R Paterson; Kristy L Jackson; Malathi S I Dona; Gabriella E Farrugia; Bruna Visniauskas; Anna M D Watson; Chad Johnson; Minolfa C Prieto; Roger G Evans; Fadi J Charchar; Alexander R Pinto
Journal:  Hypertension       Date:  2021-09-20       Impact factor: 10.190

6.  Interleukin-10 negatively modulates extracellular signal-regulated kinases 1 and 2 in aorta from hypertensive mouse induced by angiotensin II infusion.

Authors:  Alecsander F Bressan; Gisele A Fonseca; Rita C Tostes; R Clinton Webb; Victor Vitorino Lima; Fernanda Regina Giachini
Journal:  Fundam Clin Pharmacol       Date:  2018-09-07       Impact factor: 2.748

7.  Interleukin-10 does not contribute to the anti-contractile nature of PVAT in health.

Authors:  R K Kumar; L M Kaiser; C E Rockwell; S W Watts
Journal:  Vascul Pharmacol       Date:  2021-02-01       Impact factor: 5.738

8.  Inflammation and oxidative stress markers in diabetes and hypertension.

Authors:  Chloé Pouvreau; Antoine Dayre; Eugene G Butkowski; Beverlie de Jong; Herbert F Jelinek
Journal:  J Inflamm Res       Date:  2018-02-19

Review 9.  Immunity and Hypertension.

Authors:  Rong M Zhang; Kyle P McNerney; Amy E Riek; Carlos Bernal-Mizrachi
Journal:  Acta Physiol (Oxf)       Date:  2020-06-25       Impact factor: 6.311

10.  Mechanisms of vascular dysfunction in the interleukin-10-deficient murine model of preeclampsia indicate nitric oxide dysregulation.

Authors:  Hajrunisa Cubro; Karl A Nath; Sonja Suvakov; Oscar Garcia-Valencia; Santosh Parashuram; Wendy M White; Tracey L Weissgerber; Meryl C Nath; Natasa M Milic; Fernando Sontag; Livius V d'Uscio; Yi Zhu; James L Kirkland; Tamar Tchkonia; Mariam P Alexander; Reade A Quinton; Zvonimir S Katusic; Joseph P Grande; Vesna D Garovic
Journal:  Kidney Int       Date:  2020-11-02       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.